Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 7/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479755 | 0.75 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL12483925 | 0.75 | KDM4E (0.42) | CYP24A1CYP26A1LMNAGAACYP27A1 | |
| SCHEMBL5480832 | 0.73 | LMNA (0.48) | LMNAGAAMTNR1ASIGMAR1NQO2 | |
| SCHEMBL15724892 | 0.73 | LMNA (0.50) | LMNAGAACYP19A1MTNR1ASIGMAR1 | |
| SCHEMBL6787435 | 0.72 | KDM4E (0.49) | CYP24A1CYP26A1LMNAGAACYP27A1 | |
| SCHEMBL503654 | 0.72 | SIGMAR1 (0.57) | LMNAGAACYP19A1MTNR1ASIGMAR1 | |
| SCHEMBL10467454 | 0.71 | KDM4E (0.48) | CYP24A1CYP26A1LMNAGAACYP27A1 | |
| SCHEMBL12480312 | 0.70 | ACHE (0.52) | LMNAGAA | |
| SCHEMBL6301799 | 0.69 | CYP19A1 (0.53) | CYP24A1LMNAGAACYP27A1CYP19A1 | |
| SCHEMBL10163625 | 0.69 | LMNA (0.51) | LMNAGAACYP19A1MTNR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185323-A1 | Method of preparing benzazepines and derivatives thereof | ECOLE POLYTECHNIQUE (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185323-A1 | Method of preparing benzazepines and derivatives thereof | CYP2F1, MAOB, CYP1A2 | CYP24A1 2858/4885CYP26A1 213/4885LMNA 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.